| |
Total
|
2006
|
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
p value
|
|---|
|
Patients number
|
1263
|
195
|
162
|
210
|
184
|
188
|
189
|
135
| |
|
Age, years
|
64.5 ± 14.0
|
60.2 ± 14.8
|
63.5 ± 12.9
|
63.5 ± 14.1
|
65.9 ± 14.1
|
64.8 ± 13.5
|
67.8 ± 13.3
|
66.6 ± 13.9
|
.000
|
|
Male, %
|
65
|
65
|
65
|
68
|
63
|
68
|
60
|
64
|
.722
|
|
Diabetes, %
|
46
|
50
|
48
|
43
|
51
|
44
|
42
|
45
|
.517
|
|
BMI, kg/m2
|
23.1 ± 4.7
|
22.6 ± 5.5
|
23.1 ± 3.9
|
22.7 ± 3.4
|
23.1 ± 4.5
|
23.7 ± 6.4
|
22.9 ± 4.6
|
23.8 ± 4.2
|
.212
|
|
Duration of nephrologist care, days
|
625
|
552
|
432
|
608
|
566
|
697
|
796
|
775
|
.109
|
|
[174, 1557]
|
[83, 1789]
|
[175, 1450]
|
[185, 1346]
|
[138, 1356]
|
[160, 1860]
|
[206, 1530]
|
[254, 1827]
|
|
Vascular access, %
|
70
|
68
|
70
|
70
|
69
|
68
|
68
|
77
|
.615
|
|
Primary disease, %
|
.000
|
|
Diabetic nephropathy
|
44
|
47
|
48
|
42
|
47
|
43
|
40
|
40
| |
|
Glomerulonephritis
|
21
|
31
|
17
|
25
|
15
|
18
|
18
|
23
| |
|
Nephrosclerosis
|
16
|
7
|
17
|
10
|
19
|
19
|
25
|
22
| |
|
PCK
|
4
|
2
|
5
|
4
|
3
|
5
|
5
|
2
| |
|
Others
|
16
|
14
|
14
|
20
|
17
|
16
|
13
|
13
| |
|
Systolic BP, mmHg
|
155 ± 25
|
152 ± 25
|
159 ± 24
|
154 ± 25
|
153 ± 26
|
155 ± 25
|
154 ± 23
|
156 ± 25
|
.222
|
|
Diastolic BP, mmHg
|
78 ± 14
|
77 ± 13
|
80 ± 14
|
79 ± 13
|
76 ± 14
|
79 ± 14
|
78 ± 14
|
81 ± 14
|
.067
|
|
CTR, %
|
53.3 ± 6.7
|
52.6 ± 6.5
|
53.9 ± 6.3
|
53.4 ± 6.9
|
53.7 ± 6.6
|
53.5 ± 6.4
|
52.9 ± 7.9
|
53.2 ± 6.2
|
.659
|
|
Hemoglobin, g/dL
|
8.7 ± 1.5
|
8.5 ± 1.6
|
8.6 ± 1.3
|
8.6 ± 1.6
|
8.7 ± 1.4
|
8.6 ± 1.5
|
9.0 ± 1.5
|
9.1 ± 1.4
|
.002
|
|
Hemoglobin/dose of ESAa
|
0.46
|
0.48
|
0.43
|
0.43
|
0.58
|
0.58
|
0.46
|
0.40
|
.050
|
|
[0.35, 0.72]
|
[0.35, 0.71]
|
[0.35, 0.70]
|
[0.35, 0.69]
|
[0.38, 0.77]
|
[0.38, 0.73]
|
[0.33, 0.76]
|
[0.27, 0.73]
|
|
Albumin, g/dL
|
3.3 ± 0.5
|
3.3 ± 0.5
|
3.3 ± 0.5
|
3.4 ± 0.5
|
3.3 ± 0.5
|
3.3 ± 0.5
|
3.4 ± 0.5
|
3.4 ± 0.5
|
.153
|
|
Creatinine, mg/dL
|
9.4 ± 3.2
|
9.8 ± 3.8
|
9.7 ± 3.5
|
9.1 ± 2.9
|
9.4 ± 3.2
|
9.1 ± 3.1
|
9.3 ± 3.1
|
9.6 ± 3.0
|
.228
|
|
eGFR, mL/min/1.732
|
5.1 ± 2.2
|
5.2 ± 2.2
|
5.0 ± 1.9
|
5.4 ± 2.1
|
5.2 ± 2.9
|
5.3 ± 1.8
|
5.0 ± 1.9
|
4.8 ± 1.9
|
.280
|
|
Total cholesterol, mg/dL
|
172 ± 50
|
177 ± 53
|
180 ± 53
|
170 ± 47
|
170 ± 42
|
169 ± 56
|
171 ± 52
|
168 ± 44
|
.401
|
|
Triglyceride, mg/dL
|
111
|
113
|
110
|
106
|
114
|
103
|
126
|
109
|
.272
|
|
[81, 157]
|
[80, 156]
|
[79, 167]
|
[79, 201]
|
[81, 152]
|
[76, 161]
|
[88, 163]
|
[83, 149]
|
|
HDL-C, mg/dL
|
48 ± 16
|
49 ± 18
|
50 ± 19
|
48 ± 15
|
46 ± 14
|
49 ± 17
|
49 ± 16
|
46 ± 15
|
.223
|
|
Calcium, mg/dL
|
7.8 ± 0.9
|
7.8 ± 1.0
|
7.8 ± 1.0
|
7.9 ± 0.9
|
7.8 ± 0.9
|
7.8 ± 0.9
|
8.0 ± 0.9
|
7.8 ± 0.9
|
.092
|
|
Phosphate, mg/dL
|
6.1 ± 1.6
|
6.1 ± 1.6
|
5.9 ± 1.5
|
5.9 ± 1.4
|
6.1 ± 1.7
|
6.1 ± 1.5
|
6.0 ± 1.6
|
6.4 ± 1.5
|
.045
|
|
Ca x P product
|
47 ± 13
|
47 ± 13
|
46 ± 13
|
46 ± 12
|
46 ± 14
|
47 ± 12
|
48 ± 14
|
49 ± 15
|
.260
|
|
i-PTH, pg/mL
|
271
|
210
|
264
|
300
|
285
|
272
|
266
|
331
|
.000
|
|
[169, 414]
|
[141, 346]
|
[179, 382]
|
[170, 425]
|
[185, 416]
|
[171, 426]
|
[159, 393]
|
[188, 468]
|
|
CRP, mg/dL
|
0.10
|
0.10
|
0.10
|
0.10
|
0.08
|
0.10
|
0.10
|
0.13
|
.000
|
|
[0.04, 0.17]
|
[0.04, 0.15]
|
[0.0, 0.14]
|
[0.0, 0.13]
|
[0.02, 0.10]
|
[0.02, 0.20]
|
[0.05, 0.20]
|
[0.05, 0.20]
|
|
Glucose, mg/dL
|
137 ± 52
|
142 ± 61
|
144 ± 61
|
135 ± 47
|
136 ± 53
|
137 ± 49
|
130 ± 47
|
139 ± 44
|
.243
|
|
Fe, μg/dL
|
67 ± 35
|
66 ± 36
|
64 ± 31
|
69 ± 33
|
68 ± 33
|
70 ± 37
|
66 ± 35
|
66 ± 39
|
.772
|
|
TIBC, μg/dL
|
233 ± 46
|
229 ± 46
|
239 ± 41
|
236 ± 51
|
229 ± 49
|
230 ± 48
|
231 ± 42
|
236 ± 43
|
.352
|
|
Ferritin, ng/dL
|
117
|
117
|
111
|
141
|
110
|
124
|
126
|
101
|
.309
|
|
[57, 209]
|
[61, 199]
|
[56, 194]
|
[68, 232]
|
[51, 114]
|
[57, 225]
|
[56, 213]
|
[42, 187]
|
|
ESA, %
|
78
|
81
|
74
|
77
|
79
|
79
|
80
|
80
|
.810
|
|
long-acting ESA, %
|
15
|
0
|
0
|
0
|
0
|
2
|
49
|
80
|
.000
|
|
Dose of ESA, per month
|
12,000
|
12,000
|
12,000
|
24,000
|
12,000
|
12,000
|
24,000
|
24,000
|
.001
|
|
[12,000, 24,000]
|
[12,000, 24,000]
|
[12,000, 24,000]
|
[12,000, 24,000]
|
[12,000, 24,000]
|
[12,000, 24,000]
|
[12,000, 24,000]
|
[12,000, 33,000]
|
|
ARB/ACE-I, %
|
64
|
56
|
67
|
69
|
61
|
70
|
65
|
61
|
.051
|
|
Vitamin D, %
|
31
|
26
|
34
|
271
|
23
|
36
|
32
|
41
|
.007
|
|
AST-120, %
|
19
|
17
|
18
|
27
|
19
|
19
|
16
|
14
|
0.054
|
|
Iron, %
|
19
|
31
|
18
|
20
|
18
|
14
|
23
|
19
|
.403
|
- Data are expressed as the mean ± SD, median [interquartile range], or percentage
-
BMI body mass index, PCK polycystic kidney disease, BP blood pressure, CTR cardiothoracic ratio, eGFR estimated glomerular filtration rate, HDL-C high density lipoprotein, i-PTH intact parathyroid hormone, CRP C-reactive protein, TIBC total iron-binding capacity, ESA erythropoiesis-stimulating agents, ARB angiotensin receptor blocker, ACE-I angiotensin-converting enzyme inhibitor
-
aHemoglobin was corrected by dose of ESA per 1000units
